Mr Richard Skells

Cambridge University Hospitals NHS Foundation Trust
CRUK Therapeutic Discovery Laboratories
University of Cambridge

NHS or other affiliations: 
Cambridge University Hospitals NHS Foundation Trust

Position: Senior Clinical Trials Coordinator
Personal home page:
Email:   richard.skells@addenbrookes.nhs.uk

PubMed journal articles - click here

Research description: 

Responsible for management and oversight of the growing portfolio of Uro-Oncology studies coordinated by CCTU and Cambridge Cancer Trials Centre.

Research Programme or Virtual Institute: 
Urological Malignancies Virtual Institute
Tumour type interests: 
Pancreas
Prostate

Key publications: 

(ESMO) P. Corrie, W. Qian, A. Gopinathan, M. Williams, R. Brais, J.W. Valle, B. Basu, S. Falk, C. Iwuji, H. Wasan, D. Palmer, M. Scott-Brown, J. Wadsley, S. Arif, L. Bax, P. Bundi, R. Skells, A. Neesse, D. Tuveson, D. Jodrell; 738P
Strong tumour cytidine deaminase (CDA) staining predicts for improved survival associated with sequential nab-Paclitaxel (nabP) and gemcitabine (GEM) chemotherapy as first line treatment of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC), Annals of Oncology, Volume 28, Issue suppl_5, 1 September 2017, mdx369.121,

(NCRI) Pippa Corrie, Wendi Qian, Aarthi Gopinathan, Juan W. Valle, Bristi Basu, Stephen Falk, Chinenye Iwuji, Harpreet Wasan, Daniel Palmer, Martin Scott-Brown, Jonathan Wadsley, Seema Arif, John Bridgewater, David Propper, Roopinder Gillmore, Michael Williams, Rebecca Brais, Katy Dalchau, Lisa Bax, Purity Bundi, Richard Skells, Andrea Machin, Albrecht Neesse, David Tuveson, Duncan Jodrell. Scheduling nab-paclItaxEl combined with GEmcitabine as first line treatment for metastatic pancreatic adenocarcinoma (mPDAC) in the SIEGE randomised trial: a test of bench to bedside concept, Abstract, NCRI 2017